Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q1)Jun 30, 2025 | (FY)Mar 31, 2025 | (Q3)Dec 31, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -2.52%878.84B | 4.13%3.56T | 3.49%897B | 5.96%901.56B | -0.38%3.42T | 843.78B | -1.52%866.78B | -2.66%855.11B | 0.91%850.83B | 19.42%3.43T |
| Cost of revenue | -3.76%356.98B | 1.37%1.47T | 0.47%383.38B | 4.42%370.92B | 1.35%1.45T | 351.6B | 1.60%381.57B | -0.26%363.58B | 2.20%355.21B | 17.27%1.43T |
| Gross profit | -1.65%521.86B | 6.17%2.09T | 5.86%513.61B | 7.07%530.64B | -1.62%1.96T | 492.18B | -3.83%485.2B | -4.36%491.53B | -0.00%495.62B | 21.02%2T |
| Operating expense | -8.61%368.12B | 2.12%1.6T | -0.60%373.96B | 7.72%402.82B | -5.48%1.56T | 436.46B | -7.71%376.23B | -7.40%375.35B | -0.61%373.96B | 30.01%1.65T |
| Selling and administrative expenses | -3.14%375.1B | 2.45%1.56T | 2.07%372.66B | 4.44%387.26B | -5.11%1.52T | --415B | -10.37%365.1B | -8.50%370.45B | -1.41%370.81B | 28.23%1.6T |
| -General and administrative expense | -3.14%375.1B | 2.45%1.56T | 2.07%372.66B | 4.44%387.26B | -5.11%1.52T | --415B | -10.37%365.1B | -8.50%370.45B | -1.41%370.81B | 28.23%1.6T |
| Other operating expenses | -90.84%1.58B | -17.07%39.83B | -83.28%2.11B | 302.36%17.25B | -10.86%48.04B | --25.66B | 643.28%12.61B | 418.43%5.49B | 292.13%4.29B | 133.86%53.89B |
| Total other operating income | 406.69%8.56B | -54.16%3.39B | -45.84%801M | 49.47%1.69B | 62.05%7.39B | --4.2B | 5.72%1.48B | 2.30%577M | 19.32%1.13B | 101.99%4.56B |
| Operating profit | 20.28%153.74B | 21.87%490.54B | 28.15%139.65B | 5.07%127.82B | 16.91%402.53B | 55.72B | 12.47%108.97B | 7.00%116.18B | 1.91%121.66B | -9.14%344.3B |
| Net non-operating interest income (expenses) | -49.03%7.17B | 81.13%45.41B | -48.44%6.5B | 63.71%14.06B | 22.60%25.07B | -10.88B | 61.84%12.6B | 396.24%14.76B | 1,522.35%8.59B | 1,436.54%20.45B |
| Non-operating interest income | -44.38%8.79B | 0.19%56.04B | -45.65%7.57B | 60.99%15.8B | 120.33%55.93B | --15.99B | 55.39%13.94B | 275.10%16.19B | 632.24%9.81B | 807.90%25.39B |
| Non-operating interest expense | -6.64%1.62B | -65.57%10.63B | -19.39%1.08B | 41.85%1.73B | 525.18%30.86B | --26.87B | 12.93%1.34B | 6.56%1.43B | -37.19%1.22B | 14.10%4.94B |
| Net investment income | ||||||||||
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
| Income from associates and other participating interests | -402.83%-1.96B | -549.71%-8.81B | -66.38%-970M | -2,261.11%-389M | -145.00%-1.36B | -634M | -157.95%-583M | 87.12%-157M | -98.61%18M | -43.67%3.01B |
| Special income (charges) | ||||||||||
| Other non-operating income (expenses) | ||||||||||
| Income before tax | 12.33%158.95B | 23.67%527.14B | 19.99%145.18B | 8.62%141.49B | 15.90%426.24B | 44.21B | 14.49%120.99B | 18.53%130.78B | 8.50%130.26B | -3.91%367.77B |
| Income tax | 8.22%38.04B | 66.07%118.98B | 87.17%26.22B | 10.00%35.15B | -25.44%71.65B | 10.18B | -48.61%14.01B | -36.67%15.5B | -8.60%31.95B | 13.02%96.1B |
| Net income | 13.69%120.91B | 15.11%408.16B | 11.20%118.95B | 8.18%106.35B | 30.52%354.6B | 34.03B | 36.43%106.97B | 34.27%115.28B | 15.52%98.31B | -8.75%271.67B |
| Net income continuous operations | 13.69%120.91B | 15.11%408.16B | 11.20%118.95B | 8.18%106.35B | 30.52%354.6B | --34.03B | 36.43%106.97B | 34.27%115.28B | 15.52%98.31B | -8.75%271.67B |
| Noncontrolling interests | 68.35%-25M | -136.52%-344M | -116.48%-101M | -131.73%-79M | -49.68%942M | -186M | 17.66%613M | -54.62%265M | -60.16%249M | 110.57%1.87B |
| Net income attributable to the company | 13.63%120.94B | 15.51%408.5B | 11.93%119.05B | 8.53%106.43B | 31.08%353.65B | 34.22B | 36.55%106.36B | 34.88%115.01B | 16.09%98.06B | -9.11%269.8B |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 13.63%120.94B | 15.51%408.5B | 11.93%119.05B | 8.53%106.43B | 31.08%353.65B | 34.22B | 36.55%106.36B | 34.88%115.01B | 16.09%98.06B | -9.11%269.8B |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 21.48%83.97 | 20.11%271.44 | 17.57%79.98 | 11.41%69.12 | 34.05%225.99 | 22.51 | 39.98%68.03 | 38.71%73.46 | 18.22%62.04 | -7.20%168.59 |
| Diluted earnings per share | 22.38%83.24 | 20.38%268.32 | 17.31%78.69 | 10.73%68.02 | 33.12%222.9 | 22.12 | 39.05%67.08 | 37.57%72.54 | 17.50%61.43 | -7.40%167.44 |
| Dividend per share | 0 | 4.35%24 | 0 | 0 | 4.55%23 | 11.5 | 0 | 4.55%11.5 | 0 | 4.76%22 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |